Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy

NCT04652258 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped too few patients could be included

Conditions

Pyrexia

Interventions

DRUG: Actemra

Sponsor

University of Zurich